Eli Lilly's Taltz beats J&J's Tremfya in psoriasis head-to-head — but the marketing brawl is just beginning
Eli Lilly has come out swinging at J&J, staking out its challenger position in a crowded battle of plaque psoriasis blockbusters.
In a Phase IV head-to-head study with 1,027 patients, Lilly says its IL-17A inhibitor Taltz beat J&J’s IL-23/p19 drug Tremfya on complete skin clearance at week 12 as defined by PASI 100. It’s the first direct comparison of these two classes using PASI 100 as a primary endpoint, Lilly says, though it also shows that Taltz is consistently superior in measures of PASI 50, PASI 75 and PASI 90 at multiple (although not all) time points — comprising a number of “key secondary endpoints.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
